+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the safety and effectiveness of combining anti-CD19 CAR T-cell therapy with Lenalidomide for adults with relapsed or refractory chronic lymphocytic leukemia CLL who have previously been treated with Ibrutinib. This Phase III open-label study aims to explore treatment safety, tolerability, pharmacokinetics, and measures of response including remission and survival rates. Participants receive Ibrutinib daily for three months before CAR T-cell infusion. Before leukapheresis, they are given Obinutuzumab to reduce circulating CLL cells. Lymphodepletion chemotherapy is administered prior to a single infusion of escalating doses of autologous CAR T cells. Lenalidomide is taken orally in the first week after infusion. Depending on measurable residual disease status at day 28, patients receive additional Lenalidomide with Obinutuzumab consolidation or Lenalidomide maintenance therapy over several cycles. Throughout the study, participants undergo safety monitoring for adverse events such as cytokine release syndrome and infections. Researchers assess overall response rates, progression-free and overall survival, and minimal residual disease negativity using flow cytometry. The study lasts up to 24 months to evaluate long-term safety and treatment effects.

Age: 18Years +All GendersPhase 1Phase 2
1 location